PellePharm is a biotechnology company committed to targeting rare dermatologic diseases, including Gorlin Syndrome and High-Frequency Basal Cell Carcinomas (BCCs), at their source.
Founded by world leaders in hedgehog signaling, PellePharm is working to improve the quality of life for those suffering from regular, debilitating surgeries by providing an easy-to-use topical solution that eliminates this need and provides an overall better quality of life.
The standard of care for these diseases is surgery. In particular, people with severe Gorlin Syndrome may have as many as 30 surgeries per year, which can be repetitive and scarring.
PellePharm’s patidegib gel has shown early promise in a phase 2 clinical study for the mitigation of the BCC tumors in Gorlin Syndrome by blocking the disease at its source within the hedgehog signaling pathway. Because oral formulations for this treatment typically have serious systemic side effects which cause many patients to discontinue treatment, patidegib is formulated as a topical gel to reduce its side effect profile due to its minimal systemic exposure.
PellePharm is located in San Francisco, California.
For more information about PellePharm, please visit us at www.pellepharm.com.
Founded by world leaders in hedgehog signaling, PellePharm is working to improve the quality of life for those suffering from regular, debilitating surgeries by providing an easy-to-use topical solution that eliminates this need and provides an overall better quality of life.
The standard of care for these diseases is surgery. In particular, people with severe Gorlin Syndrome may have as many as 30 surgeries per year, which can be repetitive and scarring.
PellePharm’s patidegib gel has shown early promise in a phase 2 clinical study for the mitigation of the BCC tumors in Gorlin Syndrome by blocking the disease at its source within the hedgehog signaling pathway. Because oral formulations for this treatment typically have serious systemic side effects which cause many patients to discontinue treatment, patidegib is formulated as a topical gel to reduce its side effect profile due to its minimal systemic exposure.
PellePharm is located in San Francisco, California.
For more information about PellePharm, please visit us at www.pellepharm.com.
Location: United States, California, San Francisco
Employees: 11-50
Founded date: 2016
Investors 2
| Date | Name | Website |
| - | Aisling Ca... | aislingcap... |
| - | EcoR1 Capi... | ecor1cap.c... |
Mentions in press and media 3
| Date | Title | Description |
| 31.10.2014 | Funding Roundup: Which biotech, medtech and healthIT startups got investments this week? | $33 million in equity raised, closing out a $48 million Series E round The funding will bring Aileron candidate ALRN-6924 – a drug that works to activate a solid tumor suppressor protein called p53 – to clinical trial. The company says its ... |
| - | A livestock-poison-turned-drug might save her from endless cancer surgeries. But if she helps test it, could she afford to keep taking it? | Eros Dervishi for STAT PHILADELPHIA — What propelled Kaylene Sheran up to the microphone was an overwhelming exhaustion of surgery. At 19, she’d had so much of her surface excised that she was sometimes surprised to have any skin left. It w... |
| - | Funding Roundup: Which biotech, medtech and healthIT startups got investments this week? | Each week, many millions are invested into life sciences startups. There are so many that often, they get lost in the weeds. We’re keeping track for you – based on regulatory filings reported to the SEC. Here are the new funding notices fro... |